Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 8Colorectal Neoplasms 7Lung Neoplasms 6Prostatic Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Fallopian Tube Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡